This article (1) has been retracted at the request of the editors. An internal review by the editors found that the same image was used to represent Total VEGFR-2 in lanes 1–6 and in lanes 7–12 in Fig. 2A, and the same image was used to represent VEGFR-1 in lane 1 of Supplementary Figs. S2B and S4A. In addition, there appears to be splicing in the image of the Phospho-VEGFR-1 Western blot in Fig. 2A between the Lung EC and Liver EC samples and in the image of β-actin in Supplementary Fig. S4A between the Normal lung and Lung metastases samples. These splicing alterations were noted when applying adaptive histogram equalization to the figure using image analysis software.
A copy of this Retraction Notice was sent to the last known email addresses for all seven authors. One author (Daniel L. Karl) agreed to the retraction; one author (Sam S. Yoon) did not agree to the retraction; five authors (Yoon-Jin Lee, Ugwuji N. Maduekwe, Courtney Rothrock, Sandra Ryeom, and Patricia A. D’Amore) did not respond.
Footnotes
Reference
- 1.Lee Y-J, Karl DL, Maduekwe UN, Rothrock C, Ryeom S, D’Amore PA, et al. Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res 2010;70:83 57–67. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]